BSX vs MDLN stock comparison
Boston Scientific vs. Medline · data as of November 13, 2026
Boston Scientific (BSX) has a market value of about $64.3B, Medline (MDLN) about $51.9B. Over their latest twelve months Boston Scientific had revenue of $21.1B and Medline $30.7B.
On our five checks Boston Scientific scores higher: 3.0 out of 5 (average) against 1.0 (weak).
By area, the stronger company is Boston Scientific on value; Boston Scientific on future growth; Boston Scientific on track record; Boston Scientific on financial health.
Boston Scientific is cheaper on earnings (P/E 18.8 vs. 89.7).
Boston Scientific leads on 14 of the compared lines and Medline on 6.
Side by side
| BSX | MDLN | |
|---|---|---|
| Size and price | ||
| Market cap | $64.3B | $51.9B |
| Share price | $44.34 | $39.47 |
| Score | ||
| Overall score (of 5) | 3.0 | 1.0 |
| Value | 3 | 0 |
| Future growth | 5 | 2 |
| Track record | 2 | 0 |
| Financial health | 4 | 2 |
| Shareholder returns | 1 | 1 |
| Valuation | ||
| P/E (TTM) | 18.8 | 89.7 |
| Forward P/E | 14.4 | 26.2 |
| Price / free cash flow | 19.3 | 27.4 |
| Price / sales | 3.1 | 1.7 |
| EV / EBITDA | 14.1 | 22.6 |
| PEG | — | — |
| DCF value vs. price | −58% | −48% |
| Business | ||
| Revenue | $21.1B | $30.7B |
| Net income | $3.5B | $566M |
| Free cash flow | $3.3B | $1.9B |
| Net margin | 16.6% | 1.8% |
| Gross margin (5-yr avg.) | 68.9% | 26.4% |
| ROIC (5-yr avg.) | 5.9% | 8.6% |
| Growth | ||
| Revenue growth (1 yr) | 19.9% | 11.5% |
| Revenue growth (5 yrs, per year) | 15.2% | — |
| EPS growth (5 yrs, per year) | — | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$11.3B | -$9.1B |
| Dividend yield | None | None |
| Shareholder yield | 0.0% | 0.1% |
| Analysts | ||
| Upside to average target | +12% | +15% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: BSX TTM to September 30, 2026, MDLN TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Boston Scientific or Medline?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Boston Scientific scores 3.0 out of 5 and Medline 1.0; the table shows where each one is stronger.
Is Boston Scientific cheaper than Medline?
On trailing earnings, Boston Scientific trades at a P/E of 18.8 and Medline at 89.7, so Boston Scientific is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Full Boston Scientific analysis → Full Medline analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.